Tag: Prescription Drugs

Displaying 41 - 60 of 191 results.

Pages

Akorn, Inc. has agreed to sell its rights to develop, manufacture, and market the generic injectable tuberculosis drug, rifampin, in order to settle FTC charges that Akorn’s proposed acquisition of VersaPharm Inc. and its parent company, VPI Holdings Corp., would likely be...
Valeant Pharmaceuticals International, Inc. and Precision Dermatology, Inc. agreed to sell or relinquish rights to Precision’s branded single-agent topical tretinoins and generic Retin-A, common acne treatments, to settle FTC charges that Valeant’s proposed $475 million acquisition...
Pharmaceutical companies Actavis plc and Forest Laboratories, Inc. agreed to sell or relinquish their rights to four generic pharmaceuticals that treat hypertension, angina, cirrhosis, and prevent seizures to settle FTC charges that Actavis’s acquisition of Forest likely would be...
In a recently published article, we discuss our finding that generic drug companies successfully use low-pricing strategies to discourage entry by new competitors in certain circumstances.
Brief of the Federal Trade Commission as Amicus Curiae before the United States District Court for the Eastern District of Pennsylvania, addressing whether a branded company's commitment not to launch an authorized generic in competition with a generic company can constitute a...
Increased competition from the Internet has raised a concern of product quality for online prescription drugs. The Food and Drug Administration (FDA) prohibits the importation of unapproved drugs into the US and the National Association of Boards of Pharmacy (NABP) emphasizes their...
Akorn Enterprises, Inc. and Hi-Tech Pharmacal, Inc. will sell the rights and assets to three generic prescription eye medications and two generic topical anesthetics to Watson Laboratories, Inc., to settle Federal Trade Commission charges that Akorn’s proposed $640 million acquisition of Hi-Tech...
Akorn Enterprises, Inc. and Hi-Tech Pharmacal, Inc. agreed to sell the rights and assets to three generic prescription eye medications and two generic topical anesthetics to Watson Laboratories, Inc., to settle FTC charges that Akorn’s proposed $640 million acquisition of Hi-Tech...
A few minutes ago, FTC Chairwoman Edith Ramirez delivered opening remarks to kick off today’s FTC workshop exploring emerging issues affecting competition and patient access to biologic medicines. You can view a live webcast of the workshop on the FTC’s website, or follow live tweets...
Tomorrow, the FTC will host a workshop to explore emerging issues affecting competition and consumer access to biologic medicines.
Thermo Fisher Scientific Inc. (Thermo Fisher), a leading manufacturer of products used in scientific research, has agreed to sell assets to GE Healthcare to settle Federal Trade Commission charges that its proposed $13.6 billion acquisition of Life Technologies Corporation (Life) would likely...
Pharmaceutical companies Endo Health Solutions Inc. (Endo) and Boca Life Science Holdings, LLC and Boca Pharmacal, LLC (Boca) have agreed to a settlement resolving Federal Trade Commission charges that Endo’s acquisition of Boca would be anticompetitive. Under the settlement, the companies will...
Pharmaceutical companies Endo Health Sciences Inc. (Endo) and Boca Life Science Holdings, LLC and Boca Pharmacal, LLC (Boca) agreed to a settlement resolving FTC charges that Endo’s acquisition of Boca would be anticompetitive.
Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Mylan, Inc.’s acquisition of Agila Specialties Global Pte. Ltd and Agila Specialties Pvt. Ltd. (collectively, Agila) from Strides Arcolab Ltd.
Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Actavis, Inc’s proposed acquisition of Warner Chilcott plc would reduce competition in the U.S. markets for four current and future pharmaceuticals. They are:
When faced with a major illness, patients usually want the best medicine available, regardless of cost. In some cases, next-generation “biologic” medicines may be the best treatments available. Unfortunately, these critical treatments can be very expensive. For example, Herceptin,...

Pages